Press Releases

TargaZyme, Inc. Announces  Receipt of An SBIR Award from the National Institute of Dental and Craniofacial Research For the Development of TZ 101 Treated Mesenchymal Stem Cells for Treatment of Oral Mucositis

San Diego, CA August 26, 2014 – TargaZyme, Inc. (formerly America Stem Cell, Inc.)  a clinical-stage biopharmaceutical company developing novel enzyme technologies and products to improve efficacy outcomes for cancer immunotherapy and cell therapy, announced today the receipt of an SBIR award to fund  the  development of genetically-modified mesenchymal stem cells treated with Targazyme’s lead product, TZ101 for treatment of oral mucositis. This SBIR award is from the […]

TargaZyme, Inc. Appoints Christopher Calhoun to Business Advisory Board

San Diego, CA  June 3, 2014  — TargaZyme, Inc. (formerly America Stem Cell, Inc. or the “Company”), a clinical-stage biopharmaceutical company developing enzyme platform technologies/products  to improve efficacy outcomes for cell therapy and cancer immunotherapy,  announced today that it has appointed Christopher Calhoun to its Business Advisory Board.

Chris Calhoun is a co-founder of Cytori Therapeutics. He has served as its Vice-Chairman/Director and Chief Executive Officer.

Lynnet Koh, Chairman & CEO of  TargaZyme, Inc., stated “Mr. Calhoun is a visionary entrepreuneur, a proven public company CEO with a successful track record with major […]

San Antonio, TX   February 5, 2014  — Targazyme, Inc. (formerly America Stem Cell, Inc.) has been selected to present at the 2014 BIO CEO & Investor Conference being held in New York City on February 10-11, 2014.  The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded and select private biotech companies. Targazyme is a privately held clinical-stage biopharmaceutical company developing and commercializing breakthrough products designed to improve outcomes for patients receiving cell therapy.  Targazyme will be presenting in the oncology track for private companies to some of the most influential […]

SAN ANTONIO TX DEC 4, 2013.
America Stem Cell, Inc. (ASC) today announced that three presentations will be made at the upcoming American Society of Hematology (ASH) meeting in New Orleans, LA December 7-10, 2013 on its lead product, ASC-101. ASC-101 is currently undergoing evaluation in a dual umbilical cord blood transplantation study evaluating ASC-101 in patients with hematologic malignancies and myelodysplastic syndrome at The University of Texas MD Anderson Cancer Center. To date, 16 patients have been transplanted with cord blood that was treated with ASC-101 immediately prior to transplant. On the basis of interim data, ASC received clearance from the U.S. Food and Drug Administration […]

SAN ANTONIO, TX JANUARY 7, 2013.

America Stem Cell, Inc (ASC) today announced that it has been awarded an Advanced Technology Small Business Innovation Research (SBIR) grant from the National Heart Lung and Blood Institute at the National Institutes of Health. This grant will be led by Dr. Leonard Miller, VP Preclinical Research at ASC, in collaboration with Dr. Larry Sherman at the Oregon National Primate Research Center, Oregon Health & Science University (OHSU). Dr. Sherman’s lab has over 15 years of extensive experience in multiple models of demyelinating diseases such as multiple sclerosis (MS), and in the application of […]